Cbst v Hsp 20130201 - Cc Charts Joint

7/30/2019 Cbst v Hsp 20130201 - Cc Charts Joint

1/40

IN THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF DELAWARE

CUBIST PHARMACEUTICALS, INC.,

Plaintiff,

v.

HOSPIRA, INC.,

Defendant.

)

)

)

))

)

)

))

C.A. No. 12-367 (GMS)

(CONSOLIDATED)

JOINT CLAIM CONSTRUCTION CHARTS FOR THE PATENTS BEING

ASSERTED BY CUBIST PHARMACEUTICALS, INC.

The parties have met and conferred, and present the following Joint Claim Construction

Charts for the patents being asserted by Cubist Pharmaceuticals, Inc.

I. Stipulated Constructions. During the meet and confer process, the parties

agreed to the claim construction for twelve claim terms from U.S. Patent Nos. 6,468,967,

6,852,689, RE39,071, 8,129,342, and 8,058,238 as set forth in Exhibit A. The parties jointly and

respectfully submit that, if the Court deems it appropriate, the Court include these agreed-upon

claim constructions in the ultimate claim construction order. In the alternative, the parties agree


2/40

MORRIS,NICHOLS,ARSHT &TUNNELL LLP

/s/ Maryellen NoreikaJack B. Blumenfeld (#1014)Maryellen Noreika (#3208)

1201 North Market Street

P.O. Box 1347Wilmington, DE 19899

(302) 658-9200

[email protected]@mnat.com

PHILLIPS, GOLDMAN & SPENCE, P.A.

/s/ John C. Phillips, Jr.John C. Phillips, Jr. (No. 110)

Megan C. Haney (No. 5016)

1200 North Broom StreetWilmington, DE 19806

Tel. (302) 655-4200

Fax (302) [email protected]

[email protected]

OF COUNSEL:

William F. Lee

Lisa J. PirozzoloEmily Whelan

WILMER

CUTLER

PICKERING

HALE

AND DORRLLP60 State Street

Boston, MA 02109

(617) 526-6000

Attorneys for Plaintiff Cubist Pharmaceuticals,

Inc.

OF COUNSEL:

James F. HurstWINSTON & STRAWN LLP35 W. Wacker DriveChicago, Illinois 60601

(312) 558-5600E-mail: [email protected]

Gail J. StandishPeter E. PerkowskiWINSTON & STRAWN LLP333 S. Grand Avenue, Suite 3800

Los Angeles, California 90071

(213) 615-1700E-mail:[email protected]

E-mail: [email protected]


3/40

1

Exhibit A

List of Agreed Upon Claim Term Constructions for U.S. Patent Nos. 6,468,967, 6,852,689, RE39,071, 8,129,342, and 8,058,238

Claim Term Agreed-Upon Construction

U.S. Patent Nos. 8,058,238 and 8,129,342

daptomycin that is substantially free of [another compound]

(Claims 3-5, 7-9, 50, 55, 56, 58, 61, 62, 64, 87, 88, 90, 165-175 ofthe 238 patent)

(Claims 10, 11, 16 of the 342 patent)

the other compound is present in an amount that is no more than1% of the amount of the daptomycin preparation

daptomycin that is essentially free of [another compound]

(Claims 4-5, 9, 50, 56, 59, 62, 65, 88, 91, 165-175, 190 of the 238

patent)

(Claims 3, 32, 42 of the 342patent)

the other compound is present in an amount that is no more than0.5% of the amount of the daptomycin preparation

anhydro-daptomycin

(Claims 3-5, 7, 50, 55, 56, 61, 62, 87, 88, 165-175, 190 of the 238patent)

(Claims 1, 3-16, 18, 21-23, 32, 33, 41, 42, 53 of the 342 patent)

The daptomycin derivative in which the -aspartyl group ofdaptomycin is transpeptidated to an anhydro-succinimido group,

i.e.,


4/40

2


-isomer of daptomycin

(Claims 3-5, 7, 50, 55, 56, 61, 62, 87, 88, 165-175 of the 238patent)

(Claims 1, 3-16, 21-23, 32, 33, 41, 42, 53 of the 342 patent)

The daptomycin derivative that contains a -aspartyl group

instead of an -aspartyl group, i.e.,

micelle / daptomycin micelle

(Claims 21-35, 37-40, 42-45, 99, 104, 106, 107, 108, 131, 138,143, 145, 146, 147, 165-174, 176-180, 184, 185 of the 238 patent)

(Claims 22-23, 30-49 of the 342 patent)

aggregates of amphipathic molecules / aggregates comprisingdaptomycin

aggregate / daptomycin aggregate

(Claims 3-5, 7-9, 49-52, 55, 56, 58, 59, 61, 62, 64, 65, 85, 87, 88,

90-109, 113-123, 125-148, 151-161, 164-175, 179, 183-187, 189,190 of the 238 patent)

(Claims 1, 3-23, 25-29, 50-54 of the 342 patent)

associated molecules including but not limited to micelles /

associated molecules comprising daptomycin including but notlimited to daptomycin micelles

conditions effective to form daptomycin [micelles/aggregates]

(Claims 3-5, 7-9, 37-40, 42-43, 93-107, 125-146, 166-174,

conditions that result in the formation of daptomycinmicelles/aggregates, including but not limited to one or more of the

daptomycin concentration, temperature, salt concentration, and/or

pH of a daptomycin solution


5/40

3


176-179 of the 238 patent)

(Claims 5-6 of the 342 patent)

daptomycin purified by a process comprising the steps of:

(Claims 3-5, 7, 166-174 of the 238 patent)

(Claims 30-39, 50-54 of the 342 patent)

daptomycin that has been purified by a process including, but notlimited to, the following steps

daptomycin that is free of [another compound]

(Claims 50, 165-175 of the 238 patent)

the other compound is present in an amount that is no more than

0.1% of the amount of the daptomycin preparation

essentially pure daptomycin

(Claims 50, 165-175 of the 238 patent)

at least 98% of a sample is daptomycin

purified daptomycin

(Claims 8-9, 49-52, 55, 56, 58, 59, 61, 62, 64, 65, 85, 87,88, 90-109, 113-123, 125-148, 151-161, 164-180, 183-

187, 189, 190 of the 238 patent)

daptomycin that is substantially pure, essentially pure, or

substantially free, essentially free, or free of another compound

U.S. Patent No. RE 39,071

a combination of a compound of formula 1, a compound offormula 2, and a compound of formula 3

(Claims 18, 19, 26, 28 of the 071 patent)

a compound of formula 1, a compound of formula 2, and acompound of formula 3, present together and totaling 100% by

weight of the combination


6/40

1

Exhibit B

Summary of Proposed Claim Constructions for U.S. Patent Nos. 6,468,967, 6,852,689, 8,129,342, 8,058,238, and RE39,071

Term To Be Construed Cubists Proposed Construction Hospiras Proposed Construction

U.S. Patent Nos. 6,468,967, 6,852,689, 8,129,342, and 8,058,238

daptomycin

(Claims 3-5, 16-17, 27-28, 34-35,

42-45 of the 967 patent)

(Claims 48-52 of the 689 patent)

(Claims 3-5, 7-9, 21-35, 37-40, 42-45,

49-52, 55, 56, 58, 59, 61, 62, 64, 65,85, 87, 88, 90-109, 113-123, 125-148,

151-161, 164-180, 183-187, 189, 190of the 238 patent)

(Claims 1, 3-23, 25-54 of the 342

patent)

The cyclic lipopeptide antibiotic derived fromthe fermentation of Streptomyces roseosporus,

comprised of a decanoyl side chain linked to the

N-terminal tryptophan of a cyclic 13-amino acidpeptide, i.e.,

(LY146032) or a pharmaceutically acceptablesalt thereof.

The compound described in the Baltzarticle at Fig. 1a (Biotechnology of

Antibiotics, 2nd

Ed., ed. by Strohl,

415-435 (1997)) and in the Tally articleat Fig. 1 (Exp. Opin. Invest. Drugs,

8:1223-1238 (1999)), (i.e., having the

L-Asn configuration)


7/40

2

Term To Be Construed Cubists Proposed Construction Hospiras Proposed Construction

U.S. Patent No. RE39,071

formula 3 compound / compound offormula 3

(Claims 18, 26, 28 of the 071 patent)

An A21978C cyclic peptide of

wherein RN

is n-decanoyl (i.e., LY 146032).

The FORMULA 3 compound asrecited in claims 18 and 26 thatre-issued on April 18, 2006 (i.e.,

having the L-Asn configuration)


8/40

1

Exhibit C

Joint Claim Chart for U.S. Patent Nos. 6,468,967, 6,852,689, 8,129,342, and 8,058,238

Proposed Construction of Disputed Claim Term with Citations to Supporting Evidence

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

Daptomycin

(Claims 3-5,

16-17, 27-28,34-35, 42-45 of

the 967 patent)

(Claims 48-52 of

the 689 patent)

(Claims 3-5, 7-9,

21-35, 37-40,42-45, 49-52, 55,

56, 58, 59, 61, 62,64, 65, 85, 87, 88,

90-109, 113-123,125-148,151-161, 164-180,

183-187, 189, 190

of the 238 patent)

(Claims 1, 3-23,

25-54 of the 342

The cyclic lipopeptide

antibiotic derived from thefermentation of Streptomyces

roseosporus, comprised of adecanoyl side chain linked to

the N-terminal tryptophan of acyclic 13-amino acid peptide,i.e.,

(LY146032) or apharmaceutically acceptable

salt thereof.

967 Patent Specification

Col. 1, lns. 10-13

Col. 1, lns. 18-51

Col. 1, ln. 63Col. 2, ln.

43

Col. 3, lns. 14-28

Col. 3, lns. 36-41

Col. 3, ln. 45Col. 4, ln.48

Col. 4, ln. 64Col. 5, l.13

Col. 5, lns. 41-56

Col. 5, l. 65Col. 6, ln. 1

Col. 6, lns. 9-12

The compound describedin the Baltz article at Fig.

1a (Biotechnology ofAntibiotics, 2nd Ed., ed. by

Strohl, 415-435 (1997))

and in the Tally article atFig. 1 (Exp. Opin. Invest.

Drugs, 8:1223- 1238(1999)), (i.e., having the

L-Asn configuration)

967 Patent and FileHistory

Abstract

Col. 1, ln. 2Col. 3,ln. 12

Col. 14, lns. 38-48

Baltz et al.,Biotechnology of

Antibiotics, 2nd

Ed., ed.by Strohl, 415-435

(1997) (cited at Col. 1,lns. 40-51)

Tally et al., Exp. Opin.

Invest. Drugs,

8:1223-1238 (1999)(cited at Col. 1, lns.

20-38)

9/11/00 Declaration of


9/40

2

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

patent) Col. 6, lns. 17-38


2

Col. 8, lns. 8-12

Col. 8, lns. 15-17

Col. 8, lns. 21-46

Col. 9, ln. 25Col. 12,ln. 30 (Examples 1, 2)

Col. 12, ln. 62Col. 14,

ln. 27 (Examples 4, 5)

Col. 14, ln. 50Col. 15,ln. 2 (Claims 1-7)

Col. 15, ln. 27Col. 16,

ln. 29 (Claims 12-28)

Col. 16, lns. 33-62(Claims 32-45)

Figures 1-3

967 Patent Abstract

Francis Tally at 5-6

238 Patent and File

History

Abstract

Col. 1, ln. 21Col. 3,ln. 46

Col. 7, lns. 2-27

Col. 37, lns. 30-40

Claims 49, 50, 66, and

191

Baltz et al.,Biotechnology of

Antibiotics, 2nd

Ed., ed.by Strohl, 415-435

(1997) (cited at Col. 1,

lns. 58-66)

Tally et al., Exp. Opin.

Invest. Drugs,

8:1223-1238 (1999)(cited at Col. 1, lns.

39-57)

U.S. Patent No. RE


10/40

3

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

967 Patent File History

9/11/2000 Amendment

and Response to OfficeAction at pp. 6-21

(CUBH 000794-809)

9/11/2000 Declaration of

Francis P. Tally Under 37C.F.R. 1.132 at pp. 3-8

(CUBH 000812-17)

06/02/2000 InformationDisclosure Statement at p.

2 (CUBH 000845)

01/07/2002 AmendmentUnder 37 C.F.R. 1.312

at p. 2 (CUBH 000934)

References Cited in the

Specification or FileHistory of the 967 Patent

U.S. Patent No.

RE32,310

Col. 2, ln. 51Col. 11,ln. 62

32,333 to Hamill (cited

at Col. 2, lns. 13-19)

U.S. Patent No. RE32,455 to Hamill (cited

at Col. 2, lns. 13-19)

U.S. Patent No. RE

32,310 to Debono(cited at Col. 2, lns.

20-27)

U.S. Patent No. RE32,311 to Debono

(cited at Col. 2, lns.20-27)

U.S. Patent No.

4,537,717 to Abbott


U.S. Patent No.

4,482,487 to Abbott(cited at Col. 2, lns.

20-27)

U.S. Patent No.4,524,135 to Abbott

(cited at Col. 2, lns.


11/40

4

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

Col. 15, ln.45Col. 23,

ln. 62

U.S. Patent No.RE32,311

Abstract


17

Col. 17, ln. 65Col. 43,ln. 17

U.S. Patent No.

4,537,717

Abstract

Col. 1, ln. 13Col. 7, ln.68

Col. 15, ln. 10Col. 32,ln. 68

U.S. Patent No.

4,482,487

Abstract


20-27)

U.S. Patent No.

5,912,226 to Baker(cited at Col. 2, ln. 65

Col. 3, ln. 46)

Miao et al.,

DaptomycinBiosynthesis in

Streptomyces

roseosporus: Cloningand Analysis of theGene Cluster and

Revision of Peptide

Stereochemistry,Microbiology, 151:

1507-23 (2005)


12/40

5

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

61

Col. 8, ln. 53Col. 13,

ln. 42

Col. 22, ln. 32Col. 33,ln. 15

U.S. Patent No.

4,524,135

Abstract

Col. 1, ln. 13Col. 6, ln.56

Col. 8, ln. 47Col. 13,

ln. 40

Col. 21, ln. 60Col. 32,ln. 30



16

Col 19, ln. 62Col. 25,

ln. 58


13/40

6

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

U.S. Patent No.

RE32,455

Col. 1, ln. 51Col. 2, ln.25

Col. 20, ln. 4Col. 25,

ln. 65

U.S. Patent No.4,800,157

Col. 1, lns. 1-64

Col. 8, ln. 40Col. 10,

ln. 29



16


Col. 1, ln. 1Col. 8, ln. 7

U.S. Patent N. 4,208,403


14/40

7

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

Abstract


19

Baltz,LipopeptideAntibiotics Produced by

Streptomyces

roseosporus andStreptomyces fradiae,

BIOTECHNOLOGY OF

ANTIBIOTICS, 2d ed.415-435 (1997) at pp.415-16, 419-20, 423-26,

430

(HOSP_CUB0004829-30HOSP_CUB0004833-34,

HOSP_CUB0004837-40,HOSP_CUB0004844)

Tally et al.,Daptomycin:

A Novel Agent forGram-Positive Infections,EXP.OPIN.INVEST.

DRUGS 8:1223-1238(1999) at 1223, -24,

1229-35

(HOSP_CUB0005043-44HOSP_CUB0005049-55)


15/40

8

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

Oleson et al., Once-Daily

Dosing in DogsOptimizes Daptomycin

Safety, ANTIMICROBIAL

AGENTS AND

CHEMOTHERAPY, 44:

2948-2953 (2000) at pp.2948, 2951-53 (CUB

00487949, CUB

00487952-54)

Lee et al.,Daptomycinversus Conventional

Therapy in the Treatmentof Endocarditis and

Bacteremia, ABSTRACTS

OF THE INTERSCIENCECONFERENCE ON

ANTIMICROBIAL AGENTSAND CHEMOTHERAPY,

A885, 1991

Sexton et al., The Use ofDaptomycin, a

Lipopeptide Antibiotic, in

the Treatment of GramPositive Infections in

Man, ABSTRACTS OF THEINTERSCIENCE

CONFERENCE ON


16/40

9

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

ANTIMICROBIAL AGENTS

AND CHEMOTHERAPY,A932, 1988


Col. 1, lns. 13-16

Col. 1, lns. 21-53

Col.1, ln. 65Col. 2, ln.

45

Col. 3, lns. 17-30

Col. 3, lns. 38-43

Col. 3, ln. 48Col. 4, ln.50


16

Col. 5, lns. 43-58

Col. 5, ln. 67Col. 6, ln.3

Col. 6, lns. 11-14


17/40

10

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

Col. 6, lns. 19-40


4

Col. 8, lns. 10-14

Col. 8, lns. 17-19

Col. 8, lns. 23-48

Col. 9, ln. 29Col. 12,ln. 30 (Examples 1, 2)

Col. 12, ln. 63Col. 14,

ln. 25 (Examples 4, 5)

Col. 14, lns. 48-62(Claims 1-5)

Col. 15, ln. 21Col. 16,

ln. 65 (Claims 10-57)

Figures 1-3

689 Patent Abstract


02/20/2002 InformationDisclosure Statement at p.


18/40

11

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

2 (CUBH 001680)

11/20/2002 Amendment

at pp. 6-17 (CUBH001530-41)


Specification or File

History of the 689 Patent

U.S. Patent No.

RE32,310

Col. 2, ln. 51Col. 11,

ln. 62

Col. 15, ln.45Col. 23,ln. 62

U.S. Patent No.

RE32,311

Abstract


17

Col. 17, ln. 65Col. 43,

ln. 17

U.S. Patent No.


19/40

12

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

4,537,717

Abstract


68

Col. 15, ln. 10Col. 32,ln. 68

U.S. Patent No.

4,482,487

Abstract

Col. 1, ln. 11Col. 6, ln.61

Col. 8, ln. 53Col. 13,

ln. 42

Col. 22, ln. 32Col. 33,

ln. 15

U.S. Patent No.

4,524,135

Abstract



20/40

13

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

56

Col. 8, ln. 47Col. 13,

ln. 40

Col. 21, ln. 60Col. 32,ln. 30

U.S. Patent No.

RE32,333

Col. 1, ln. 40Col. 2,ln. 16

Col 19, ln. 62Col. 25,

ln. 58



25

Col. 20, ln. 4Col. 25,ln. 65


Col. 1, lns. 1-64


21/40

14

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

Col. 8, ln. 40Col. 10,

ln. 29



16


Col. 1, ln. 1Col. 8, ln. 7

U.S. Patent N. 4,208,403

Abstract


19

Baltz,Lipopeptide

Antibiotics Produced byStreptomyces

roseosporus andStreptomyces fradiae,

BIOTECHNOLOGY OFANTIBIOTICS, 2d ed.

415-435 (1997) at pp.

415-16, 419-20, 423-26,


22/40

15

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

430

(HOSP_CUB0004829-30,

HOSP_CUB0004833-34,

HOSP_CUB0004837-40,HOSP_CUB0004844)

Tally et al.,Daptomycin:

A Novel Agent forGram-Positive Infections,

EXP.OPIN.INVEST.

DRUGS 8:1223-1238(1999) at 1223, -24,

1229-35(HOSP_CUB0005043-44

HOSP_CUB0005049-55)

Oleson et al., Once-Daily

Dosing in DogsOptimizes Daptomycin

Safety, ANTIMICROBIAL

AGENTS ANDCHEMOTHERAPY, 44:2948-2953 (2000) at pp.

2948, 2951-53 (CUB

00487949, CUB00487952-54)

Lee et al.,Daptomycin

versus Conventional


23/40

16

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

Therapy in the Treatment

of Endocarditis andBacteremia, ABSTRACTS

OF THE INTERSCIENCE

CONFERENCE ON

ANTIMICROBIAL AGENTS


Sexton et al., The Use of

Daptomycin, a

Lipopeptide Antibiotic, inthe Treatment of Gram

Positive Infections inMan, ABSTRACTS OF THE

INTERSCIENCE

CONFERENCE ONANTIMICROBIAL AGENTS


238 Patent Specification:

Fig. 1.

Col. 1, lns. 21-25

Col. 1, lns. 39-57



24/40

17

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

60

Col. 3, lns. 33-38

Col. 4, ln. 21

Col. 5, lns. 22-36

Col. 7, lns. 24-27

Col. 9, lns 9-15

Col. 9, lns. 16-22

Col. 14, lns 13-30

Col. 21, lns. 8-17

Col. 26, lns. 46-49

Col. 26, lns. 56-60

Col. 28, lns. 1-18

Cols. 30-37

238 File History

08/11/2009 Office Action

at CUBH 001937


25/40

18

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

3/16/2010 Information

Disclosure Statement atCUBH 001893


Specification or File

History of the 238 Patent


Col. 2, ln. 51Col. 11,ln. 62

Col. 15, ln. 45Col. 23,ln. 62

U.S. Patent No.

RE32,311

Abstract

Col. 1, ln. 9Col. 12, ln.17

Col. 17, ln. 65Col. 43,

ln. 17



26/40

19

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

Abstract


68

Col. 15, ln. 10Col. 32,ln. 68

U.S. Patent No.

4,482,487

Abstract

Col. 1, ln. 11Col. 6, ln.61

Col. 8, ln. 53Col. 13,

ln. 42

Col. 22, ln. 32Col. 33,ln. 15


Abstract

Col. 1, ln. 13Col. 6, ln.56

Col. 8, ln. 47Col. 13,


27/40

20

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

ln. 40

Col. 21, ln. 60Col. 32,

ln. 30


Col. 1, ln. 40Col. 2,

ln.16

Col 19, ln. 62Col. 25,ln. 58

U.S. Patent No.

RE32,455

Col. 1, ln. 51Col. 2, ln.25

Col. 20, ln. 4Col. 25,

ln. 65


Col. 1, lns. 1-64

Col. 8, ln. 40Col. 10,

ln. 29


28/40

21

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

U.S. Patent No.

4,874,843

Col. 1, ln. 1Col. 5, ln.16

U.S. Patent No.

4,885,243

Col. 1, ln. 1Col. 8, ln. 7

U.S. Patent N. 4,208,403

Abstract

Col. 1, ln. 1Col. 25, ln.19

Baltz,Lipopeptide


roseosporus and

Streptomyces fradiae,BIOTECHNOLOGY OF

ANTIBIOTICS, 2d ed.415-435 (1997) at pp.

415-16, 419-20, 423-26,

430(HOSP_CUB0004829-30

HOSP_CUB0004833-34,


29/40

22

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

HOSP_CUB0004837-40,

HOSP_CUB0004844)

Tally et al.,Daptomycin:A Novel Agent for

Gram-Positive Infections,

Exp. Opin. Invest. Drugs8:1223-1238 (1999) at pp.

1223, -24, 1229-35(HOSP_CUB0005043-44

HOSP_CUB0005049-55)

Miao et al.,DaptomycinBiosynthesis in

Streptomyces

roseosporus: Cloning andAnalysis of the Gene

Cluster and Revision of

Peptide Stereochemistry,

MICROBIOLOGY 151:

1507-23 (2005) at pp.

1507-08, 1512, 1520-21(CUBH 000441-42,CUBH 000446, CUBH

000454-55)

342 Patent Specification:

Fig. 1.


30/40

23

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

Col. 1, lns. 18-22

Col. 1, ln. 36 Col. 2, ln.

57

Col. 3, lns. 30-36

Col. 4, ln. 18

Col. 5, lns. 17-31

Col. 7, lns. 17-20

Col. 9, lns. 4-1.

Col. 9, lns 11-17

Col. 14, lns. 8-12

Col. 14, lns. 17-26

Col. 21, lns. 1-11

Col. 26, lns. 39-42

Col. 26, lns. 49-53

Col. 27, ln. 60Col. 28,

ln. 10


31/40

24

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

Cols. 30-37

342 File History

07/29/2011 Office Action

at CUBH 000283

08/12/2011 InformationDisclosure Statement at

CUBH 000199

12/08/2011 InformationDisclosure Statement at

CUBH 000192


Specification or FileHistory of the 342 Patent

Cubicin (daptomycin

for injection) Label 1004September 2003

Cubicin (daptomycin

for injection) Label1004-1Revised August

200

Cubicin (daptomycin

for injection) Label


32/40

25

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

1004-2Revised June

2005

Cubicin (daptomycinfor injection) Label

1004-10-1 August 2010

U.S. Patent No.

RE32,310

Col. 2, ln. 51Col. 11,

ln. 62

Col. 15, ln.45Col. 23,

ln. 62


Abstract


17

Col. 17, ln. 65Col. 43,

ln. 17

U.S. Patent No.

4,537,717


33/40

26

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

Abstract


68

Col. 15, ln. 10Col. 32,ln. 68

U.S. Patent No.

4,482,487

Abstract

Col. 1, ln. 11Col. 6, ln.61

Col. 8, ln. 53Col. 13,

ln. 42

Col. 22, ln. 32Col. 33,ln. 15


Abstract

Col. 1, ln. 13Col. 6, ln.56

Col. 8, ln. 47Col. 13,


34/40

27

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

ln. 40

Col. 21, ln. 60Col. 32,

ln. 30



16

Col 19, ln. 62Col. 25,ln. 58

U.S. Patent No.

RE32,455

Col. 1, ln. 51Col. 2, ln.25

Col. 20, ln. 4Col. 25,

ln. 65


Col. 1, lns. 1-64

Col. 8, ln. 40Col. 10,

ln. 29


35/40

28

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

U.S. Patent No.

4,874,843

Col. 1, ln. 1Col. 5, ln.16

U.S. Patent No.

4,885,243

Col. 1, ln. 1Col. 8, ln. 7

U.S. Patent N. 4,208,403

Abstract

Col. 1, ln. 1Col. 25, ln.19

Baltz,Lipopeptide


roseosporus and

Streptomyces fradiae,BIOTECHNOLOGY OF

ANTIBIOTICS, 2d ed.415-435 (1997) at pp.

415-16, 419-20, 423-26,

430(HOSP_CUB0004829-30

HOSP_CUB0004833-34,


36/40

29

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

HOSP_CUB0004837-40,

HOSP_CUB0004844)

Tally et al.,Daptomycin:A Novel Agent for

Gram-Positive Infections,

Exp. Opin. Invest. Drugs8:1223-1238 (1999) at pp.

1223, -24, 1229-35(HOSP_CUB0005043-44

HOSP_CUB0005049-55)

Miao et al.,DaptomycinBiosynthesis in

Streptomyces

roseosporus: Cloning andAnalysis of the Gene

Cluster and Revision of


MICROBIOLOGY 151:

1507-23 (2005) at pp.

1507-08, 1512, 1520-21(CUBH 000441-42,CUBH 000446, CUBH

000454-55)


37/40

1

Exhibit D

Joint Claim Chart for U.S. Patent Nos. RE39,071

Proposed Construction of Disputed Claim Term with Citations to Supporting Evidence

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

formula 3

compound/compound of

formula 3

(Claims 18, 26,28 of the 071

patent)

An A21978C cyclic

peptide of

wherein RN is n-decanoyl


Abstract

Col. 1, lns. 26-35

Col. 2, lns. 29-31

Col. 7, ln. 1Col. 8, ln. 25

Col. 8, lns. 46-67

Col. 15, ln. 50Col. 17,

ln. 4 (Claim 18)

Col. 17, ln. 8Col. 19,

ln. 30 (Claim 20)

Col. 20, ln. 26Col. 22,

ln. 45 (Claim 26)

Col. 23, ln. 1Col. 26,ln. 6 (Claim 30)

01/29/2008 Certificate of

The FORMULA 3compound as recited in

claims 18 and 26 thatre-issued on April 18, 2006

(i.e., having the L-Asn

configuration)

071 Patent and FileHistory

Abstract

Col. 1, lns. 14-35

Col. 1, ln. 60Col. 2, ln.31

Col. 6, ln. 56Col. 7, ln.60

Col. 8, lns. 50-60

Col. 9, ln. 47Col. 10, ln.

67

Claims 1, 2, 18, 20, 26, 30

as re-issued on April 18,

2006

6/10/87 PatentApplication at 11


38/40

2

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

(i.e., LY 146032). Correction



Correction (CUBH000436)

10/18/2007 Request for

Certificate of Correction atpp. 1-4 (CUBH

000437-40) andAttachment at pp.1507-08, 1512, 1520-21

(CUBH 000442-42,CUBH 000446, CUBH

000454-55)

References Cited in

Specification orProsecution History of the

071 Patent

U.S. Patent No. 4,885,243

Col. 2, lns. 9-15

Col. 2, lns. 20-25

Col. 2, lns. 33-42

5/5/88 Office Action at 4

11/16/88 Amendment at

5-6

9/5/89 Amendment at 6

12/12/89 Office Action at4

6/28/90 Amendment at

5-6

9/14/90 Office Action at2

8/14/91 Office Action at

2-4

11/13/91 Amendment 3,5, 7

9/1/92 Declaration ofManuel Debono at 2-3

11/5/92 Office Action at

3

3/9/93 Response at 3, 6, 8

5/27/93 Appeal Brief at 5,


39/40

3

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

Col. 3, ln. 57Col. 8, ln. 7

(Examples 1-10)


Col. 2, lns. 54-57

Col. 17, lns. 20-22


Col. 1, lns. 64-67

Miao et al.,Daptomycin

Biosynthesis in

Streptomycesroseosporus: Cloning and

Analysis of the Gene

Cluster and Revision ofPeptide Stereochemistry,

MICROBIOLOGY 151:1507-23 (2005) at pp.

1507-08, 1512, 1520-21(CUBH 000441-42,

CUBH 000446, CUBH

000454-55)

11

12/5/93 Reply Brief at 2

3/5/98 BPAI Decision at

6-7, 10

4/11/00 ReissueApplication at 4-5, claims

18, 26

8/22/00 Office Action at6-8


Correction Request at 1-2

1/29/08 Certificate ofCorrection

U.S. Patent No.

4,208,403 to Hamill


U.S. Patent No.

4,537,717 to Abbott(cited at Col. 7, lns.

42-60)

U.S. Patent No.


40/40

4

Term To Be

Construed

Cubists Proposed

Construction

Intrinsic Evidence

Supporting Cubists

Construction

Hospiras Proposed

Construction

Intrinsic Evidence

Supporting Hospiras

Construction

4,399,067 to Debono

(cited in 5/5/88 OfficeAction)

U.S. Patent No. RE

32,311 to Debono (cited

in 5/5/88 Office Action)

U.S. Patent No.5,912,226 to Baker (cited

in 4/11/00 Reissue

Application)

U.S.A.N and the USP

Dictionary of DrugNames (1989) (cited as

Exhibit 1 in 6/28/90

Amendment)

Miao et al., DaptomycinBiosynthesis in

Streptomycesroseosporus: Cloning and

Analysis of the GeneCluster and Revision of


Microbiology, 151:1507-23 (2005)

Cbst v Hsp 20130201 - Cc Charts Joint

Documents

Transcript of Cbst v Hsp 20130201 - Cc Charts Joint